• 68593 Citations
1976 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with well-defined targets (BRAF v600, NRAS mutations, CKIT mutations). I co-lead the Northwestern Cancer Center Translational Research in Solid Tumors (TRIST) program which is critical to the success of the Cancer Center. In this role, I am working to bring translational studies including immunotherapy based trials to all solid tumors. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is my highest priority. As Co-Leader of TRIST program, I am determined to bring creative immune based trials to cancers .

Training Experience

1982Internship, University of Chicago Hospitals
1985Residency, University of Chicago Hospitals
1986Residency, University of Wisconsin Hospital & Clinics
1989Fellowship, University of Wisconsin Hospital & Clinics

Education/Academic qualification

MD, Albert Einstein College

… → 1981

Research interests

  • Genomic Medicine/Personalized Medicine
  • Immunology
  • Kidney Cancer / Urinary Tract Cancer
  • Skin Cancer

Fingerprint Dive into the research topics where Jeffrey Alan Sosman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

Open Access
  • Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: A case report and review of the literature

    Kosche, C., Stout, M., Sosman, J., Lukas, R. V. & Choi, J. N., 2020, (Accepted/In press) In : Melanoma Research. p. 313-316 4 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors

    Wang, L. X., Quach, H. T., Moodabigil, N. V., Davis, E. J., Sosman, J. A., Dusetzina, S. B. & Johnson, D. B., Jan 15 2020, In : Cancer. 126, 2, p. 322-328 7 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies

    Zhai, L., Bell, A., Ladomersky, E., Lauing, K. L., Bollu, L., Sosman, J. A., Zhang, B., Wu, J. D., Miller, S. D., Meeks, J. J., Lukas, R. V., Wyatt, E. J., Doglio, L., Schiltz, G. E., McCusker, R. H. & Wainwright, D. A., Jun 16 2020, In : Frontiers in immunology. 11, 1185.

    Research output: Contribution to journalReview article

    Open Access
  • Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines

    Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Kaffenberger, B. H., Lunning, M., McGettigan, S., McPherson, J., Mohindra, N. A., Naidoo, J., Olszanski, A. J., Oluwole, O. & 12 others, Patel, S. P., Pennell, N., Reddy, S., Ryder, M., Santomasso, B., Shofer, S., Sosman, J. A., Wang, Y., Weight, R. M., Johnson-Chilla, A., Zuccarino-Catania, G. & Engh, A., 2020, In : JNCCN Journal of the National Comprehensive Cancer Network. 18, 3, p. 231-241 11 p.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations